JP2024521127A5 - - Google Patents

Info

Publication number
JP2024521127A5
JP2024521127A5 JP2023572110A JP2023572110A JP2024521127A5 JP 2024521127 A5 JP2024521127 A5 JP 2024521127A5 JP 2023572110 A JP2023572110 A JP 2023572110A JP 2023572110 A JP2023572110 A JP 2023572110A JP 2024521127 A5 JP2024521127 A5 JP 2024521127A5
Authority
JP
Japan
Application number
JP2023572110A
Other languages
Japanese (ja)
Other versions
JP2024521127A (ja
JPWO2022245933A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/029819 external-priority patent/WO2022245933A1/en
Publication of JP2024521127A publication Critical patent/JP2024521127A/ja
Publication of JPWO2022245933A5 publication Critical patent/JPWO2022245933A5/ja
Publication of JP2024521127A5 publication Critical patent/JP2024521127A5/ja
Pending legal-status Critical Current

Links

JP2023572110A 2021-05-19 2022-05-18 テストステロン補充治療を実現するための好ましい経口ウンデカン酸テストステロン療法 Pending JP2024521127A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190609P 2021-05-19 2021-05-19
US63/190,609 2021-05-19
PCT/US2022/029819 WO2022245933A1 (en) 2021-05-19 2022-05-18 Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Publications (3)

Publication Number Publication Date
JP2024521127A JP2024521127A (ja) 2024-05-28
JPWO2022245933A5 JPWO2022245933A5 (https=) 2025-05-27
JP2024521127A5 true JP2024521127A5 (https=) 2025-05-27

Family

ID=84140782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572110A Pending JP2024521127A (ja) 2021-05-19 2022-05-18 テストステロン補充治療を実現するための好ましい経口ウンデカン酸テストステロン療法

Country Status (10)

Country Link
US (1) US20230398128A1 (https=)
EP (1) EP4340846A4 (https=)
JP (1) JP2024521127A (https=)
KR (1) KR20240027602A (https=)
AU (2) AU2022277557B2 (https=)
BR (1) BR112023024162A2 (https=)
CA (1) CA3219547A1 (https=)
IL (1) IL308658A (https=)
MX (1) MX2023013734A (https=)
WO (1) WO2022245933A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2519230T3 (pl) 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
EP2968137B1 (en) 2013-03-15 2021-11-10 Marius Pharmaceuticals LLC Emulsion formulations
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2519230T3 (pl) * 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
US20200197412A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US11564933B2 (en) * 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency

Similar Documents

Publication Publication Date Title
JP2024521127A5 (https=)
CL2025003837A1 (es) Anticuerpo monoclonal o fragmento unión a antígeno del mismo que se une específicamente a axl
CL2025003429A1 (es) Correa para máquina de pulpa o papel con sensores para detectar la presión durante el funcionamiento.
BR102023008688A2 (https=)
BR202022009269U2 (https=)
BY13167U (https=)
BY13172U (https=)
CN307045816S (https=)
CN307045787S (https=)
CN307047453S (https=)
CN307045470S (https=)
CN307044820S (https=)
CN307044255S (https=)
CN307047489S (https=)
CN307047769S (https=)
BY24001C1 (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13160U (https=)
BY13174U (https=)
BY13161U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13163U (https=)